StageZero Life Sciences Ltd.
StageZero Life Sciences Ltd. (SZLSF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
szlsf · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for StageZero Life Sciences Ltd. (SZLSF) measures how much investors pay for each dollar of the company's trailing earnings. SZLSF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.11.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
StageZero Life Sciences Ltd.You SZLSF | $1M | N/A | — | -$0.11 |
 Cann American Corp. CNNA | $1M | 0.19x | -96.8% | $0.01 |
 Enzolytics Inc. ENZC | $4M | N/A | — | -$0.00 |
 Epigenomics AG EPGNF | $1M | N/A | — | -$0.36 |
 Anything Technologies Media, Inc. EXMT | $2M | N/A | — | -$0.00 |
 IDenta Corp. IDTA | $1M | 7.15x | +16.2% | $0.02 |
 InVitro International IVRO | $2M | 11.12x | +80.7% | $0.01 |
Industry Average 3 peers with valid PE | — | 6.15x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.11 | — | |
2021-12-31 FY2021 | — | $-0.11 | — | |
2020-12-31 FY2020 | — | $-0.15 | — | |
2019-12-31 FY2019 | — | $-0.13 | — | |
2018-12-31 FY2018 | — | $-0.23 | — | |
2017-12-31 FY2017 | — | $-0.24 | — | |
2016-12-31 FY2016 | — | $-0.72 | — | |
2015-12-31 FY2015 | — | $-0.90 | — | |
2014-12-31 FY2014 | — | $-1.12 | — | |
2013-12-31 FY2013 | — | $-2.07 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for StageZero Life Sciences Ltd. (SZLSF) measures how much investors pay for each dollar of the company's trailing earnings. SZLSF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.11.
Frequently asked questions
SZLSF pe ratio · 6 questionsSZLSF's current PE ratio is N/A as of 2026-06-15, based on a stock price of $0.01 and TTM EPS of -$0.11. Data sourced from Financial Modeling Prep via SZLSF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · StageZero Life Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15